Therapeutic drug monitoring of monoclonal antibodies in inflammatory and malignant disease: Translating TNF-α experience to oncology

Lack of response to monoclonal antibodies (mAbs) has been associated with inadequate mAb serum concentrations. Therapeutic drug monitoring (TDM) of mAbs has the potential to guide to more effective dosing in individual patients. This review discusses the mechanisms responsible for interpatient varia...

Full description

Saved in:
Bibliographic Details
Published in:Clinical pharmacology and therapeutics 2016-04, Vol.99 (4), p.419-431
Main Authors: Oude Munnink, TH, Henstra, MJ, Segerink, LI, Movig, KLL, Brummelhuis-Visser, P
Format: Article
Language:English
Subjects:
Anti-Inflammatory Agents - administration & dosage
Anti-Inflammatory Agents - adverse effects
Anti-Inflammatory Agents - blood
Anti-Inflammatory Agents - pharmacokinetics
Antibodies, Monoclonal - administration & dosage
Antibodies, Monoclonal - adverse effects
Antibodies, Monoclonal - blood
Antibodies, Monoclonal - pharmacokinetics
Antineoplastic Agents - administration & dosage
Antineoplastic Agents - adverse effects
Antineoplastic Agents - blood
Antineoplastic Agents - pharmacokinetics
Drug Dosage Calculations
Drug Monitoring - methods
Humans
Molecular Targeted Therapy
Tumor Necrosis Factor-alpha - antagonists & inhibitors
Tumor Necrosis Factor-alpha - immunology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Lack of response to monoclonal antibodies (mAbs) has been associated with inadequate mAb serum concentrations. Therapeutic drug monitoring (TDM) of mAbs has the potential to guide to more effective dosing in individual patients. This review discusses the mechanisms responsible for interpatient variability of mAb pharmacokinetics, summarizes exposure‐response data of mAbs used in inflammatory and malignant disease, presents current evidence of mAb‐TDM in inflammatory disease, and provides hurdles and required future steps for further implementing mAb‐TDM.
ISSN:0009-9236
1532-6535
DOI:10.1002/cpt.211